Check SCREEN READER MODE to make this survey compatible with screen readers.
Vitamin C in the critically ill (VitC)
Recent publications on vitamin C have focused on the rise of its use in the treatment of the critically ill. The search for the best treatment or the best adjuvant treatment for patients in a refractory situation is a primary objective of these. Despite good initial results and a pathophysiological basis, the efficiency of vitamin C treatments has not been conclusively proven in recent randomized clinical trials. This has meant that the Surviving Sepsis Campaign does not recommend its use. Therefore, although we do not expect vitamin C to be used by a majority of survey respondents, we do expect it to be used in refractory septic shock or have some relevance in local protocols on management of septic shock.
In this survey we also examine how vitamin C is being used to treat critically ill patients with other conditions; there is often less evidence available in these situations, however, we consider that since the pathophysiological basis is the same, the information gathered may lead us to propose future randomized studies on other types of non-septic critical patients.
This survey, endorsed by ESICM, will enable us to understand the impact of the use of vitamin C as an adjunctive treatment for the inflamed critically ill patient, as well as for other critically ill patients (those with ARDS, severe pneumonia due to SARS-CoV-2). The results will help us to explore the possibility of conducting multicenter studies on the use of vitamin C in the future. Thank you very much for participating.
The Vit-C survey team: Luis Chiscano–Camón (survey Lead, Vall d'Hebron Hospital, Barcelona, Spain), Ricard Ferrer Roca, Juan Carlos Ruiz Rodriguez, Mette M. Berger, Elke Gunnar, Pedro Povoa.